VGI Health Technology Limited

NSX:VTL ISIN:AU0000152597

VGI Health Technology LimitedVGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

 
 
 

View in Other Languages

News

VGI Health Technology Limited (NSX:VTL) New Partnership

🕔2/14/2024 3:08:00 PM 1764

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has entered into a non-binding Heads of Agreement with Hebei Visual Medical Technology Co. Ltd, marking a significant step in VTL's distribution strategy into the market of the People's Republic of China.

Read Full Article

VGI Health Technology Limited (NSX:VTL) HREC Approval for Phase II Clinical Study

🕔1/11/2024 9:04:00 AM 2497

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has received human ethics approval from the Human Research Ethics Committee of The Peter MacCallum Cancer Centre for its Phase II clinical study in Pancreatic Cancer.

Read Full Article

VGI Health Technology Limited (NSX:VTL) commences divestment of Invictus BioPharma Pty Ltd

🕔8/29/2023 11:16:00 AM 2244

VGI Health Technology Limited (NSX:VTL) commences divestment of Invictus BioPharma Pty Ltd

Read Full Article

VGI Health Technology Limited (NSX:VTL) Quarterly Update

🕔1/31/2023 8:42:00 AM 2039

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 31 December 2022.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Update on Sale of Invictus BioPharma

🕔12/21/2022 4:05:00 PM 4147

On 5 April 2022, the Directors of VGI Health Technology Limited (NSX:VTL) announced the sale of its wholly owned subsidiary, Invictus BioPharma Pty Ltd to Invictus BioPharma Holdings Ltd (IVBHL) (the Transaction).

Read Full Article

VGI Health Technology Limited (NSX:VTL) R & D Facility Agreement with Fundsquire Pty Ltd

🕔10/13/2022 3:26:00 PM 3049

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has entered into an R&D Loan Facility Agreement (Loan Facility) with Fundsquire Pty Ltd.

Read Full Article

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH Phase II Clinical Study

🕔10/5/2022 8:58:00 AM 3210

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has commenced dosing of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Receives Ethics Approval for US Clinical Study

🕔9/26/2022 8:54:00 AM 3277

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has received ethics approval to proceed with a US pharmacokinetics and exercise clinical study.

Read Full Article

VGI Health Technology Limited (NSX:VTL) NAFLD/NASH PhaseII Clinical Study Recruits 1st Patient

🕔9/14/2022 8:50:00 AM 3522

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd (Invictus), has made significant progress in its Phase II clinical study in Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic SteatoHepatitis (NASH).

Read Full Article

VGI Health Technology Limited (NSX:VTL) June 2022 Quarterly Update

🕔7/29/2022 8:57:00 AM 3071

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 30 June 2022.

Read Full Article
###

96,457 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 84) (Last 30 Days: 360) (Since Published: 94127) 

Company Data

    Headquarters
  • Suite 4, 24 Birdwood Lane
    Lane Cove NSW 2066
    Australia
  • Telephone
  • +61-2-8279-8908 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.vgiht.com

Company Reports

Quarterly Report

Download Presentation